Aethlon Medical Announces Poster Presentation At Keystone Symposium On Long COVID And Other Post-Acute Infection Syndromes; Presentation Reviews Hemopurifier Affinity Resin's Ability To Bind Extracellular Vesicles In Long COVID Samples

Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025.

Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.

Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID.  EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation.

Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.

The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered  from COVID-19 in order to examine whether  individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively.